Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about ...

Qiagen and Incyte have announced a master collaboration agreement to create a diagnostic panel to aid in the treatment of ...

Israel launches strikes on missile facilities in central Iran: air force Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and efficacy ...

Panelists discuss how to select among the four available JAK inhibitors (Ruxolitinib, Fedratinib, Pacritinib, and Momelotinib) based on patient-specific factors such as anemia, thrombocytopenia, and ...

Strategic actions by Supernus, Teva, Incyte, and BioNTech highlight growing momentum in advancing clinical-stage therapies ...

QIAGEN N.V. QGEN recently announced a new global collaboration with Incyte INCY. The partnership enhances QIAGEN’s onco-hematology diagnostics pipeline and supports Incyte’s extensive portfolio in ...

Dr. Raajit K. Rampal and Dr. Joshua K. Sabari walk through updates for patients in the treatment of blood cancers, including polycythemia vera.

The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given ...

During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia ...

Researchers at Oxford University have uncovered a potential new therapeutic target in a particularly aggressive and ...

Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.